Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.78 |
| ▸ | STK3 | Q13188 | 3/20 | 0.78 |
| ▸ | STK4 | Q13043 | 3/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.78 |
| ▸ | KDR | P35968 | 2/20 | 0.78 |
| ▸ | BTK | Q06187 | 2/20 | 0.78 |
| ▸ | STK25 | O00506 | 1/20 | 0.78 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.78 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.78 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.78 |
| ▸ | STK17B | O94768 | 1/20 | 0.78 |
| ▸ | STK10 | O94804 | 1/20 | 0.78 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18949472 | 0.93 | ERBB2 (0.89) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL18933401 | 0.93 | EGFR (0.75) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL14864932 | 0.92 | EGFR (0.76) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL14864934 | 0.91 | EGFR (0.77) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL14864937 | 0.89 | EGFR (0.78) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL18949449 | 0.88 | EGFR (0.72) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL15163655 | 0.88 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL571763 | 0.88 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL15163654 | 0.88 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC | |
| Neratinib SCHEMBL571762 | 0.88 | ERBB2 (1.00) | EGFRERBB2STK3STK4SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | disclosed |
| EP-3222620-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-09-27 | — | — | EP | disclosed |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-9676724-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | disclosed |
| EP-2581372-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246443-B2 | Cyanoquinoline derivatives | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885STK3 275/4885 |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885STK3 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.